Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Celgene Corp (CELG)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 61,332,988
  • Shares Outstanding, K 703,360
  • Annual Sales, $ 13,003 M
  • Annual Income, $ 2,940 M
  • 36-Month Beta 1.33
  • Price/Sales 4.72
  • Price/Cash Flow 11.44
  • Price/Book 17.88

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 2.00
  • Number of Estimates 2
  • High Estimate 2.01
  • Low Estimate 1.99
  • Prior Year 1.78
  • Growth Rate Est. (year over year) +12.36%

Price Performance

See More
Period Period Low Period High Performance
1-Month
86.32 +1.49%
on 09/12/18
95.30 -8.07%
on 08/31/18
-2.76 (-3.05%)
since 08/17/18
3-Month
76.28 +14.85%
on 06/28/18
95.30 -8.07%
on 08/31/18
+9.88 (+12.71%)
since 06/18/18
52-Week
74.13 +18.18%
on 05/21/18
147.17 -40.47%
on 10/02/17
-55.23 (-38.67%)
since 09/18/17

Most Recent Stories

More News
The Zacks Analyst Blog Highlights: Illumina, Celgene , Athersys and Achillion

The Zacks Analyst Blog Highlights: Illumina, Celgene , Athersys and Achillion

CELG : 87.61 (+0.47%)
ILMN : 350.88 (+1.05%)
ACHN : 3.21 (+1.58%)
ATHX : 1.87 (-0.53%)
IPOs and Foreign Investment Propel Biotech: 4 Top Picks

A steady influx of foreign as well as domestic investments in U.S. biotech has gone a long way in boosting gains for the space.

CELG : 87.61 (+0.47%)
TBIO : 10.35 (-1.71%)
ACHN : 3.21 (+1.58%)
ILMN : 350.88 (+1.05%)
NTGN : 8.72 (-1.13%)
ATHX : 1.87 (-0.53%)
Zacks.com featured highlights include: Nucor, PCM, Celgene and Rayonier

Zacks.com featured highlights include: Nucor, PCM, Celgene and Rayonier

CELG : 87.61 (+0.47%)
RYAM : 21.23 (-0.98%)
PCMI : 20.05 (-5.65%)
NUE : 64.27 (+1.93%)
Celgene (CELG) Stock Sinks As Market Gains: What You Should Know

Celgene (CELG) closed at $86.80 in the latest trading session, marking a -0.45% move from the prior day.

CELG : 87.61 (+0.47%)
Immuno Oncology & Targeted Therapy Companies Set to Breakout

HENDERSON, NV / ACCESSWIRE / September 12, 2018 / Immuno Oncology has been getting investors revved up in 2018. Abpro and Neon announced IPOs and recently, German biotech Affimed agreed to an alliance...

AFMD : 4.35 (+2.35%)
CELG : 87.61 (+0.47%)
IOVA : 13.70 (+4.58%)
Boost Your Portfolio With These 4 High Earnings Yield Stocks

Earnings yield can be used for finding out undervalued stocks.

CELG : 87.61 (+0.47%)
RYAM : 21.23 (-0.98%)
PCMI : 20.05 (-5.65%)
NUE : 64.27 (+1.93%)
Celgene Corp Set to Possibly Rebound After Yesterday's Selloff of 1.59%

Celgene Corp (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $86.45 to a high of $88.86. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $88.56...

CELG : 87.61 (+0.47%)
Watch for Celgene Corp to Potentially Rebound After Falling 1.59% Yesterday

Celgene Corp (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $86.45 to a high of $88.86. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $88.56...

CELG : 87.61 (+0.47%)
Endocyte Announces FDA's Acceptance of Trial Endpoint Change

177Lu-PSMA-617, a prostate specific membrane antigen-targeted radioligand therapy, is Endocyte's (ECYT) lead program. It is being evaluated in a phase III study for mCRPC for PSMA-positive patients

CELG : 87.61 (+0.47%)
LGND : 265.72 (+4.75%)
ECYT : 17.97 (+2.92%)
GILD : 73.67 (+1.22%)
bluebird (BLUE) Reports Updated Data on Lenti-D Gene Therapy

bluebird bio (BLUE) announces updated results from phase II/III Starbeam study of its Lenti-D gene therapy in boys aged 17 years or below with CALD.

CELG : 87.61 (+0.47%)
LGND : 265.72 (+4.75%)
BLUE : 140.00 (+2.04%)
GILD : 73.67 (+1.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade CELG with:

Business Summary

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Their portfolio of commercial products include REVLIMID, VIDAZA, THALOMID, POMALYST/IMNOVID,...

See More

Key Turning Points

2nd Resistance Point 89.11
1st Resistance Point 88.36
Last Price 87.61
1st Support Level 86.94
2nd Support Level 86.28

See More

52-Week High 147.17
Fibonacci 61.8% 119.27
Fibonacci 50% 110.65
Fibonacci 38.2% 102.03
Last Price 87.61
52-Week Low 74.13

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar